bluuebunny/crossref_metadata_2025_split huggingface dataset:
PD130 Health Technology Assessment Of Cervical Cancer Screening In Indonesia
Authors: Mongan Suzanna , Byrnes Joshua , Lam Alfred , Kim Hansoo 
Published: January 2025

IntroductionCervical cancer is the most common gynecological cancer and the second most common cancer among women in Indonesia, and its incidence is projected to increase. In 2018, the mortality rate of cervical cancer was 60 percent, since patients often have advanced stage disease at diagnosis. We aimed to identify the status and cost of cervical cancer screening in Indonesia.MethodsWe conducted a literature review with search terms relevant to cervical cancer, screening, and Indonesia in two major databases—Embase and Medline—and by citation searching through the World Health Organization (WHO) website, human papillomavirus (HPV) reports, and Indonesian reports on cervical cancer.Results
Indonesia’s national cervical cancer screening program began in 2007 and uses visual inspection with acetic acid (VIA) or the Papanicolaou (Pap) test. VIA has high sensitivity (94%) and specificity (95%). It is the preferred option due to the limited number of pathologists and its lower cost (IDR25,000 [USD1.64]), compared with the Pap test (IDR200,000 [USD13.13]) and the HPV DNA test (IDR550,000 [USD36.00] to IDR1,400,000 [USD 91.90]). VIA and the Pap test are covered by national health insurance, whereas the HPV test is not. Nevertheless, national screening coverage was less than 10 percent, with a wide regional disparity due to the limited number of screening providers, resource constraints, and lack of awareness.ConclusionsIn Indonesia, VIA is the primary screening method because of its affordability, accessibility, and applicability in low-resource settings. However, low screening coverage has led to a high incidence of cervical cancer. New policies and incentives are needed to ensure adequate numbers of screening providers and monitoring systems. Health technology assessment can help choose cost-effective strategies for primary HPV DNA testing.
PD151 Informal Networking For Health Technology Assessment Capacity Building In African Countries
Authors: Mueller Jani , Schuller Tara 
Published: January 2025

IntroductionThe HTAfrica group is an informal network of individuals enthusiastic about health technology assessment (HTA) in Africa. In 2021, a grassroots network was founded to explore HTA issues relevant to African countries. Through webinars and information exchanges, the group aims to cultivate social capital and cohesion among members to co-create knowledge on key HTA issues that are important in the region.MethodsThe HTAfrica group uses a social media platform to convene and deliver programming. Individual users request to join and are approved by the group coordinators. Once joined, users can read and make blog posts and participate in webinars offered on relevant topics. Despite the size of the group (177 members in 2024), engagement in 2021 and 2022 was relatively low (average 3.1 people per session). In 2023, a structured eight-part introductory HTA webinar series was offered to improve engagement, in place of the ad hoc discussions on topics that were offered the previous year.ResultsEight webinars were offered to group members to introduce them to HTA and its potential importance for African countries. They included journal-based case studies of five African countries (Egypt, Ethiopia, Ghana, Malawi, and South Africa) and a concluding webinar to summarize learnings. A co-creation approach was taken where the perspectives of all participants contributed to the group’s learnings. The webinar series ended in June 2024 and had a lower participation rate (average of two per session) but = greater cohesion among participants than did the ad hoc topics approach.ConclusionsThe eight-part series was offered from October 2023 to June 2024. While the number of participants per session was lower in the structured series, the individuals formed stronger connections and gained more intangible benefits. To form a strong network, a mix of both ad hoc hot topics and a structured series approach may be optimal for the formation of looser peripheral parts of the network (ad hoc approach) as well as fostering stronger cohesion in the network core (structured series approach).
PD154 Horizon Scanning Report Identifying Technologies For Pediatric Neurological Trauma
Authors: Oparah Chizoba , Eastaugh Claire , Lanyi Kate , Hussain Amy , Woltmann James , Pearson Fiona , Still Madeleine , Brush Emily , Kolehmainen Niina 
Published: January 2025

IntroductionChildren and young people comprise one quarter of the UK’s population. Neurological trauma (e.g., traumatic brain injury and spinal cord injury) is one of the most common causes of death and disability in this population group, yet health technology innovations for these patients lag behind those for adults.MethodsUsing the horizon scanning methodologies developed by the Innovation Observatory, systematic searches were performed to identify registered clinical trials, published funding awards, and news articles that focused on innovative devices and digital and diagnostic health technologies developed for use in children and young people (from 28 days after birth up to and including 18 years of age) with actual or suspected neurological trauma. The search results were screened for relevance, and key information on the included technologies was extracted and summarized.ResultsTwenty-nine technologies were identified, of which 10 were commercially available. The majority were developed in the UK or the USA. Overall, the development pipeline was evenly split amongst technologies considered to be a device (37%), digital (34%), or diagnostic (29%). Most technologies were intended for use across settings by healthcare professionals, either for initial onsite assessment, for in-hospital management, or for rehabilitation in hospital or in the community.ConclusionsResults from this horizon scan show that development of technologies for pediatric neurological trauma is currently limited, with only a small number of the technologies being developed covering an area of unmet need. To complement the horizon scan, we also sought stakeholder insights on medical technologies for this population group. The combined results and final conclusions will be shared in a future publication.
PD155 RedETS Horizon Scanning: Impact In The Decision-Making Process
Authors: Puñal-Riobóo Janet , López-Loureiro Ignacio , Carmen Maceira Rozas María del , Acción Beatriz Casal , Faraldo Vallés María José , Roldán Margarita Segovia , Mestre-Lleixà Berta , Benguria-Arrate Gaizka , Pino-Sedeño Tasmania del , Navarro Gustavo Mora , Polo-deSantos Mar , Méndez Aurora Llanos , Guerra Jutta Knabe , Martín Sánchez Juan Ignacio , Estrada Maria-Dolors , Pastells-Peiró Roland , Galnares-Cordero Lorea , Rivero-Santana Amado , Luengo-Matos Setefilla 
Published: January 2025

IntroductionThe RedETS horizon scanning (HS) program in Spain is focused on identifying non-pharmaceutical emerging health technologies. HS is organized in three steps: (i) identification using different sources (PubMed, the biomedical press, and others); (ii) screening performed by the HS Working Group and clinicians; and (iii) prioritization using the PriTec tool. This study aimed to evaluate the accuracy of RedETS HS in identifying disruptive emerging technologies for our health system.MethodsData from brief files and full reports related to the identified emerging technologies were collected. Full health technology assessment (HTA) reports were also reviewed. The period of analysis was from 2016 to 2023. The information collected included the name, type, category, and indication of the emerging technology and the source of identification. An ad hoc Excel spreadsheet was designed to collect the information. The analysis consisted of a description of the variables and an assessment of concordance between the emerging technologies identified and those with full HTA reports.ResultsThere were 338 emerging technologies identified. These technologies were mainly therapeutic (52.1%) or diagnostic (25.7%). In addition, about 45 percent were medical devices and 15.7 percent were in vitro diagnostic tests; imaging comprised 7.4 percent. Most of the emerging technologies were identified through the biomedical press (22.2%), PubMed (23.6%) and industry (20.3%). In a preliminary analysis of these main sources, 31 percent of the technologies identified by HS had full HTA reports, with all of these being identified three years before the HTA.ConclusionsHS systems might help identify the most relevant technologies for healthcare systems, enabling them to be more ready to incorporate the new technologies. Therefore, HS must be able to detect emerging technologies that will have an impact on the health system. Periodic evaluation of the accuracy of HS programs will improve their impact in the HTA process.
PD156 Scanning The Right Horizons: Does Singapore’s Horizon Scanning Identify And Assess The Relevant Technologies?
Authors: Ng Jaryl , Ju Hong , Ng Zhen Long , Soon Swee Sung , Ng Kwong 
Published: January 2025

IntroductionIn Singapore, a horizon scanning (HS) system was established in 2020 by the Agency for Care Effectiveness (ACE) to provide early alerts of new and emerging medical technologies (medtechs) for service planning and to warn against the diffusion of low value technologies. This study compared the medtechs identified and assessed by ACE with health technology trends identified by our reference agency.MethodsMedtechs identified and assessed by ACE between 2020 and 2023 were analyzed to examine their distribution. Most of the identified medtechs were classified as digital health technologies, precision medicine, robotics, or implants. The prioritized technologies with a completed in-depth assessment were compared with the top 10 health technology trends identified in 2022 by our reference health technology assessment (HTA) agency, the Canadian Agency for Drugs and Technologies in Health (CADTH). Additionally, feedback from key stakeholders such as clinicians and policymakers on the HS reports was summarized to understand the relevance and value of the HS reports.ResultsFrom 2020 to 2023, there were 1,703 medtechs identified from various databases and manufacturer submissions. Digital health technologies were the largest proportion of technologies identified during this period, increasing from 26 percent in 2020 to 31 percent in 2023. Of the 20 evaluated technologies, 70 percent belonged to the top trending medtech fields identified by CADTH. These included artificial intelligence for diagnostics (n=5), point-of-care testing (n=4), companion diagnostics (n=2), wearables (n=2), and remote monitoring (n=1). Initial stakeholder feedback was positive, citing HS reports as being relevant for clinical practice. Some HS reports were also referenced by other policymakers to support regulatory decisions.ConclusionsIn summary, similarities were observed between medtechs identified and assessed by the ACE HS system and the top trending medtech fields identified by CADTH. Additionally, digital health technologies were the largest proportion of technologies identified by the ACE HS system in 2023. This was substantiated by feedback from our key stakeholders, indicating the relevance and value of the ACE HS work.
PD161 Distribution Patterns And Economic Assessments Of Gaucher Disease Therapies In Brazil: A National Health System Analysis (1999 to 2022)
Authors: Borin Marcus Carvalho , de Assis Acurcio Francisco , Alvares-Teodoro Juliana , Guerra Augusto 
Published: January 2025

IntroductionGaucher disease, an inherited lysosomal storage disorder, requires chronic management with enzyme replacement therapies (ERTs). In Brazil, the Unified Health System (SUS) plays a pivotal role in providing access to such treatments. This study aimed to analyze the distribution and associated costs of medications for Gaucher disease within the SUS, offering a comprehensive view of resource allocation over 23 years.MethodsUtilizing the TabNet system from the Brazilian Health Ministry, medication dispensation data from 1999 to 2022 were analyzed. In addition, annual and total expenditures on imiglucerase, miglustat, and taliglucerase alfa were evaluated using the Ambulatory Information System and the Hospital Information System databases for a cohort of patients from 2000 to 2015. Demographic factors such as sex, age, self-declared skin color, body mass index, and area of residence were correlated with spending patterns. Trends were contextualized with events that could potentially affect medication availability, such as ministry alerts and regulatory changes.ResultsThe dispensation analysis revealed a fluctuating pattern in medication distribution over the study period. The data revealed a peak in imiglucerase dispensation in the mid-2000s, followed by a stark decrease after 2010 that coincided with global shortages. Total costs from 2000 to 2015 reached USD1.138 billion, with annual expenditures averaging USD120,631.15. After 2010 there was a diversification in therapy utilization, with an increase in alternative treatments such as miglustat and taliglucerase alfa.ConclusionsThe study reveals a significant financial burden on the SUS from Gaucher disease treatments and demographic disparities. Trends in the dispensation and costs of ERTs within the SUS are a direct response to drug availability and regulatory actions, with adoption of alternative ERTs after 2010 demonstrating the system’s flexibility. Strategic health policy planning is vital for treatment sustainability and affordability.
PD169 Is China Embracing Innovation? An Analysis Of Early Access In The Boao Lecheng International Medical Pilot Zone
Authors: Leong Katherine , Macaulay Richard 
Published: January 2025

IntroductionSince 2018, medicines approved by regulators outside of China (e.g., the United States Food and Drug Administration) can be used in China’s Boao Lecheng International Medical Pilot Zone if approved by the Hainan authority. In 2019, the Implementation Plan for the Clinical Real-World Data Application Pilot was also introduced to facilitate real-world data generation in Boao Lecheng. This research examined the status of authorized medicines in Boao Lecheng.MethodsInformation on authorized medicines and insurance coverage was extracted from the Boao Lecheng Administration Bureau’s website and official WeChat account. Regulatory information was extracted from the National Medical Products Administration (NMPA) website on 31 October 2023.ResultsTo date, 101 medicines have been authorized for use in Boao Lecheng. Of these, 45 (45%) were included in the Lecheng Global Special Drug Insurance Scheme, which provides commercial supplementary insurance for Hainan citizens, and 28 (28%) had received NMPA approval. In addition, 10 (10%) were included in Boao Lecheng’s Clinical Real-World Data Application Pilot, four of which have since received NMPA marketing authorizations using the real-world data generated to support their applications (pralsetinib, trilaciclib, inclisiran, and the fluocinolone acetonide intravitreal implant). Three of these four medicines passed preliminary review for the National Reimbursement Drug List (NRDL) in 2022, and one was listed on the NRDL in 2023.ConclusionsBoao Lecheng has become a channel for providing foreign medicines with early access to the Chinese market, with a considerable proportion being covered by commercial supplementary insurance or subsequently obtaining NMPA approval. Although few products have gone through Boao Lecheng’s real-world data pilot to date, early examples show that it offers a route for local real-world data collection to support NMPA marketing authorizations.
PD171 National Health Service Wales - First UK Nation To Approve Dostarlimab For The Treatment Of Rectal Cancer
Authors: Jonas Rachel , Spears Rosie , Woodland Gail , Coulson James 
Published: January 2025

IntroductionDostarlimab is a monoclonal antibody that blocks the programmed cell death protein 1 receptor. Emerging evidence has shown complete clinical response with dostarlimab in patients with locally advanced, treatment-naïve stage II or III rectal cancer where the tumor is either mismatch repair deficient or has high microsatellite instability. Dostarlimab has the potential to replace standard treatments such as chemoradiotherapy and surgery.MethodsAs part of the One Wales medicines assessment process, a literature search was performed and the marketing authorization holder was contacted to ensure the most up-to-date information was available. Clinical experts were consulted to advise where the medicine would sit within current therapy pathways in National Health Service Wales and to ensure that outcome data could be collected if dostarlimab were approved. After reviewing the evidence, an evidence summary report was written by the All Wales Therapeutics and Toxicology Centre that included the clinical and cost effectiveness, safety, and budget impact of dostarlimab.ResultsThe One Wales Medicines Advisory Group assessed the evidence in June 2023, recommending access to dostarlimab for patients meeting the criteria for treatment. This recommendation was endorsed by the All Wales Medicines Strategy Group and ratified by the Welsh Government in August 2023. Starting and stopping criteria for dostarlimab were developed in collaboration with clinical experts to complement the One Wales decision. All patients in Wales who meet the agreed starting criteria will now be given the option for routine treatment with dostarlimab. To date, two patients have started treatment with dostarlimab, both of whom have reported treatment response at three months.ConclusionsWales is the first nation in the UK to approve routine access to dostarlimab for rectal cancer. The One Wales process allows access to dostarlimab, with the associated potential for avoiding life-changing surgery. Monitoring patient outcomes will provide real world data to enhance the immature dataset currently available on the clinical and cost effectiveness of dostarlimab for rectal cancer.
PD173 Semi-Automation Of Systematic Literature Review Title And Abstract Screening Using Text Mining And Classification Techniques
Authors: Morgan Ciara , Carey Niamh , White Arthur 
Published: January 2025

IntroductionResearchers are increasingly faced with the challenge of producing a robust systematic literature review (SLR) within the confines of time and budget. Semi-automating the title and abstract screening phase has been proposed to reduce the workload burden of SLRs. This research aimed to evaluate the efficacy of text mining and machine learning techniques in the semi-automation of the title and abstract screening phase of SLRs.MethodsTwo SLRs that had been manually screened by one screener (manual SLRs) were examined. The titles and abstracts of these SLRs were tokenized and the datasets were split into training and test sets. Support vector machines (SVM), Naïve Bayes (NB), and k-nearest neighbors (k-NN) classification machine learning models were used to predict whether documents in the test set were classed as relevant during the manual SLR. Diagnostic evaluation was carried out using Shapley Additive explanations and local interpretable model-agnostic explanations to explain the predictions of the optimal model.ResultsSVM achieved a sensitivity of one for both SLRs, successfully identifying all documents classed as relevant in the manual SLR. For one SLR, diagnostic evaluation indicated that the model used relevant features to generate its predictions. For the second SLR, the model had the tendency to predict using less relevant or misinterpreted variables. This may be because certain features (i.e., words) the model was trained on had different meanings depending on the clinical context and were present in both relevant and irrelevant citations. This demonstrates the inability of such models to extract semantic meaning from text.ConclusionsFor the second SLR, domain expertise was required to evaluate the features driving the SVM model predictions. This highlights the importance of using discretion when determining the trustworthiness of results generated by such models. This is important to researchers, who need assurance that the use of such techniques will not compromise the validity of their results.
PD174 The Emerging Role Of National Health Service England In The UK – An Access Enabler Or Barrier For Innovations?
Authors: Gassanova Aigun , Leong Katherine , Macaulay Richard 
Published: January 2025

IntroductionSince April 2017, National Health Service England (NHSE) has been granted new powers to negotiate directly with pharmaceutical companies offering innovative, high value medicines. This research systematically evaluated all innovative therapies that have undergone commercial discussions with NHSE.MethodsNHSE press releases for the period from 1 April 2017 to 10 November 2023 were screened for drug reimbursement decisions and the corresponding National Institute for Health and Care Excellence (NICE) assessments were identified. Key information was extracted, including reimbursement decision, date of decision, and type of commercial deal.Results
NHSE announced the conclusion of commercial discussions for 36 therapies (four in 2017, three in 2018, nine in 2019, two in 2020, nine in 2021, seven in 2022, and two in 2023). Of these, 27 NHSE commercial discussions were associated with positive NICE guidance; 12 of the 27 preceded the NICE final appraisal determination. In addition, three of the 36 therapies were associated with negative NICE appraisals (not recommended or non-submissions), one had an ongoing NICE assessment, and five did not go through NICE (subject to clinical commissioning policies). The specific type of agreement was not typically stated, but two were outcomes-based agreements, three were budget neutral, one was a portfolio-wide agreement, and one was a population health agreement.ConclusionsNHSE is becoming an increasingly active and important stakeholder in medicines access. The UK may become an increasingly important early launch market for certain therapies, as evidence by the Medicines and Healthcare products Regulatory Agency joining Project Orbis and the Access Consortium and Casgevy (the first CRISPR-based gene therapy) receiving its first global marketing authorization in the UK.